Chargement en cours...
Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters
Curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal, and the persistence of stable covalently closed circular DNA (cccDNA) during HBV replication is a key barrier that is hard to break through using the drugs currently approved for HBV treatment. Due to the accurac...
Enregistré dans:
| Publié dans: | Front Microbiol |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8271097/ https://ncbi.nlm.nih.gov/pubmed/34254007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmicb.2021.665184 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|